Drug utilisation by children and adolescents with mental retardation: a population study
- First Online:
- 88 Downloads
Little is known about the utilisation of drugs by mentally retarded children; population studies are even more sparse. In this study the chronic drug utilisation in children aged 4–18 years with mental retardation in a large population in the Netherlands was investigated.
Throughout all special schools and (day) care facilities for children with mental retardation in Friesland, parents/representatives were approached requesting participation of their children. Participants were interviewed about a number of aspects including medication use. For 921 of the 1,057 participants, information was available on medication use for those physical and psychiatric illnesses that bothered them or was expected to bother them for at least 3 months per year; 912 of the participants were within the age category under study: 4–18 years.
About 22% of the 912 participants used chronic medication, 47% of whom used two or more drugs. The prevalence of drug use increased with severity of mental retardation from about 17% to 49%. The exception was the 6% of children with borderline intellectual functioning: their medication prevalence was 27%. Overall, 17% of the study population used a nervous system drug, 4% used a respiratory system drug and 3% used an alimentary tract drug. Of the drugs for the nervous system, alimentary tract and respiratory tract, 32% was prescribed off-label. For 3%, we were unable to establish on/off-label use.
Chronic drug utilisation patterns in children and adolescents with mental retardation are different from those in the general paediatric population. These different patterns suggest the need for additional research.
KeywordsMental retardation Minors Drug utilisation Central nervous system agents Psychopharmacology
- 5.Ekins-Daukes S, Helms PJ, Simpson CR, Taylor MW, McLay JS (2004). Off-label prescribing to children in primary care: retrospective observational study. Eur J Clin Pharmacol 60:349–353Google Scholar
- 7.American Association on Mental Retardation (2002) Mental retardation. Definition, classification, and systems of support, 10th edn. American Association of Mental Retardation, Washington, DCGoogle Scholar
- 8.American Psychiatric Association (2000) Task force on DSM-IV. Diagnostic and statistical manual of mental disorders, DSM-IV-TR, 4th edn. American Psychiatric Association, Washington, DCGoogle Scholar
- 13.de Bildt A, Sytema S, Ketelaars C, Kraijer D, Volkmar F, Minderaa R (2003) Measuring pervasive developmental disorders in children and adolescents with mental retardation: a comparison of two screening instruments used in a study of the total mentally retarded population from a designated area. J Autism Dev Disord 33:595–605CrossRefPubMedGoogle Scholar
- 14.WHO collaborating centre for drug statistic methodology (1999) Guidelines for ATC classification and DDD assignment. WHO, Oslo. Also on http://www.whocc.no/atcddd/ (last accessed August 9, 2004)
- 15.Farmacotherapeutisch Kompas 1999: medisch farmaceutische voorlichting (1999) Centrale Medisch Pharmaceutische Commissie van de Ziekenfondsraad: Amstelveen, The NetherlandsGoogle Scholar
- 16.Schirm E, Tobi H, Zito JM, de Jong-van den Berg LTW (2001) Psychotropic medication in children: a study from the Netherlands. Pediatrics 108(2):e25. http://pediatrics.aappublications.org/cgi/reprint/108/2/e25CrossRefPubMedGoogle Scholar
- 18.Strachan DP (1995) Epidemiology In: Silvermann M (ed) Childhood asthma and other wheezing disorders. Chapman& Hall, London, pp 7–31Google Scholar
- 19.van Winckel M, Vander Stichele R, De Bacquer D, Bogaert M (1999) Use of laxatives in institutions for the mentally retarded. Eur J Clin Pharmacol 54:965–969Google Scholar
- 21.Connor DF, Fletcher KE, Swanson JM (1999) A meta-analysis of clonidine for symptoms of Attention-Deficit Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 38:1151–1559Google Scholar